Pharma Focus Asia

Predictive Oncology Partners with Cancer Research Horizons

Saturday, March 18, 2023

Predictive Oncology together with Cancer Research Horizons announce that they have partnered to drive the development of oncology drugs utilising Predictive Oncology’s PEDAL™ platform.

This collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery leading to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with global network. This potential collaboration will be a win for patients not just in the UK or US, but worldwide.

The collaboration will utilise Predictive Oncology’s PEDAL technology to evaluate Cancer Research Horizons’ pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatment with these compounds. PEDAL is an artificial intelligence and machine learning platform which makes high-confidence drug response predictions enabling a more informed selection of drug-tumour type combinations for clinical development. PEDAL increases the probability of clinical success by efficiently addressing tumour heterogeneity during pre-clinical stages.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024